6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Immunoediting is not a primary transformation event in a murine model of MLL-ENL AML

      research-article
      1 , 1 , 2
      Life Science Alliance
      Life Science Alliance LLC

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Using a conditional model of MLL-ENL–driven AML, Dudenhöffer-Pfeifer and Bryder show that NK cell and adaptive immunity influences little on leukemia initiation from normal cells. The data argue against immune escape as a universal primary transformation event in AML.

          Abstract

          Although it is firmly established that endogenous immunity can prevent cancer outgrowth, with a range of immunomodulatory strategies reaching clinical use, most studies on the topic have been restricted to solid cancers. This applies in particular to cancer initiation, where model constraints have precluded investigations of immunosurveillance and immunoediting during the multistep progression into acute myeloid leukemia (AML). Here, we used a mouse model where the chimeric transcription factor MLL-ENL can be conditionally activated in vivo as a leukemic “first-hit,” which is followed by spontaneous transformation into AML. We observed similar disease kinetics regardless of whether AML developed in WT or immunocompromised hosts, despite more permissive preleukemic environments in the latter. When assessing transformed AML cells from either primary immunocompetent or immunocompromised hosts, AML cells from all sources could be targets of endogenous immunity. Our data argue against immunoediting in response to selective pressure from endogenous immunity as a universal primary transformation event in AML.

          Related collections

          Most cited references20

          • Record: found
          • Abstract: found
          • Article: not found

          Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.

          Blocking Programmed Death-1 (PD-1) can reinvigorate exhausted CD8 T cells (TEX) and improve control of chronic infections and cancer. However, whether blocking PD-1 can reprogram TEX into durable memory T cells (TMEM) is unclear. We found that reinvigoration of TEX in mice by PD-L1 blockade caused minimal memory development. After blockade, reinvigorated TEX became reexhausted if antigen concentration remained high and failed to become TMEM upon antigen clearance. TEX acquired an epigenetic profile distinct from that of effector T cells (TEFF) and TMEM cells that was minimally remodeled after PD-L1 blockade. This finding suggests that TEX are a distinct lineage of CD8 T cells. Nevertheless, PD-1 pathway blockade resulted in transcriptional rewiring and reengagement of effector circuitry in the TEX epigenetic landscape. These data indicate that epigenetic fate inflexibility may limit current immunotherapies.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Immunological hallmarks of stromal cells in the tumour microenvironment.

            A dynamic and mutualistic interaction between tumour cells and the surrounding stroma promotes the initiation, progression, metastasis and chemoresistance of solid tumours. Far less understood is the relationship between the stroma and tumour-infiltrating leukocytes; however, emerging evidence suggests that the stromal compartment can shape antitumour immunity and responsiveness to immunotherapy. Thus, there is growing interest in elucidating the immunomodulatory roles of the stroma that evolve within the tumour microenvironment. In this Review, we discuss the evidence that stromal determinants interact with leukocytes and influence antitumour immunity, with emphasis on the immunological attributes of stromal cells that may foster their protumorigenic function.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Acute myeloid leukaemia.

              Acute myeloid leukaemia (AML) is a heterogeneous clonal disorder of haemopoietic progenitor cells and the most common malignant myeloid disorder in adults. The median age at presentation for patients with AML is 70 years. In the past few years, research in molecular biology has been instrumental in deciphering the pathogenesis of the disease. Genetic defects are thought to be the most important factors in determining the response to chemotherapy and outcome. Whereas significant progress has been made in the treatment of younger adults, the prospects for elderly patients have remained dismal, with median survival times of only a few months. This difference is related to comorbidities associated with ageing and to disease biology. Current efforts in clinical research focus on the assessment of targeted therapies. Such new approaches will probably lead to an increase in the cure rate.
                Bookmark

                Author and article information

                Journal
                Life Sci Alliance
                Life Sci Alliance
                lsa
                lsa
                Life Science Alliance
                Life Science Alliance LLC
                2575-1077
                10 July 2018
                August 2018
                10 July 2018
                : 1
                : 4
                : e201800079
                Affiliations
                [1 ]Division of Molecular Hematology, Department of Laboratory Medicine, Lund University, Lund, Sweden
                [2 ]Sahlgrenska Cancer Centre, Gothenburg University, Gothenburg, Sweden
                Author notes
                Author information
                https://orcid.org/0000-0002-8761-4237
                Article
                LSA-2018-00079
                10.26508/lsa.201800079
                6238415
                30456365
                241632c0-8a87-416c-9ddc-593ceb04444d
                © 2018 Bryder and Dudenhöffer-Pfeifer

                This article is available under a Creative Commons License (Attribution 4.0 International, as described at https://creativecommons.org/licenses/by/4.0/).

                History
                : 25 April 2018
                : 4 July 2018
                : 4 July 2018
                Funding
                Funded by: ERC consolidator;
                Award ID: LEUKEMIABARRIER
                Funded by: Swedish Medical Research Council, Swedish Cancer Society, Tobias Foundation, Knut and Alice Wallenberg Foundation;
                Categories
                Research Article
                Research Articles
                3

                Comments

                Comment on this article